Lipoprotein （a）：a vital member of blood lipid items

doi:10.3969/j.issn.1673-8640.2017.07.002

Abstract

Abstract:

Lipoprotein （a） [Lp（a）] consists of a low-density lipoprotein （LDL）-like particle and apolipoprotein （apo）（a） . The level of plasma Lp（a） is mainly determined by its genetic factors,including highly polymorphic copy number variation of kringleⅣ repeats and single nucleotide polymorphism at LPA gene locus. Due to its size variation,the standardization of Lp（a） determination is uncertain. It has been confirmed that there is an association between elevated Lp（a） and cardiovascular disease （CVD） in numerous studies. Lp（a） may have pro-inflammatory, pro-atherogenic and pro-thrombogenic properties and thus causes or promotes CVD. This review mainly focuses on Lp（a） structure,metabolism,genetics,determination and its relationship with CVD.

Key words: Lipoprotein（a）, Apolipoprotein（a）, LPA gene, Cardiovascular disease

CLC Number:

R446.1

QIAO Rui, ZHANG Jie. Lipoprotein （a）：a vital member of blood lipid items[J]. Laboratory Medicine, 2017, 32(7): 561-565.

Figures/Tables 1

References 30

[1]	MARANHÃO R C,CARVALHO P O,STRUNZ C C,et al. Lipoprotein(a):structure,pathophysiology and clinical implications[J]. Arq Bras Cardiol,2014,103(1):76-84.
[2]	KAMSTRUP P R,TYBJAERG-HANSEN A,NORDESTGAARD B G.Extreme lipoprotein(a)levels and improved cardiovascular risk prediction[J]. J Am Coll Cardiol,2013,61(11):1146-1156.
[3]	KOSCHINSKY M L,BEISIEGEL U,HENNE-BRUNS D,et al.Apolipoprotein(a)size heterogeneity is related to variable number of repeat sequences in its mRNA[J]. Biochemistry,1990,29(3):640-644.
[4]	WHITE A L,LANFORD R E.Cell surface assembly of lipoprotein(a)in primary cultures of baboon hepatocytes[J]. J Biol Chem,1994,269(46):28716-28723.
[5]	RADER D J,CAIN W,IKEWAKI K,et al.The inverse association of plasma lipoprotein(a)concentrations with apolipoprotein(a)isoform size is not due to differences in Lp(a)catabolism but to differences in production rate[J]. J Clin Invest,1994,93(6):2758-2763.
[6]	WHITE A L,RAINWATER D L,LANFORD R E.Intracellular maturation of apolipoprotein(a)and assembly of lipoprotein(a)in primary baboon hepatocytes[J]. J Lipid Res,1993,34(3):509-517.
[7]	RAAL F J,GIUGLIANO R P,SABATINE M S,et al.Reduction in lipoprotein(a)with PCSK9 monoclonal antibody evolocumab(AMG 145):a pooled analysis of more than 1 300 patients in 4 phase Ⅱ trials[J]. J Am Coll Cardiol,2014,63(13):1278-1288.
[8]	ALONSO R,ANDRES E,MATA N,et al.Lipoprotein(a)levels in familial hypercholesterolemia:an important predictor of cardiovascular disease independent of the type of LDL receptor mutation[J]. J Am Coll Cardiol,2014,63(19):1982-1989.
[9]	FRISCHMANN M E,KRONENBERG F,TRENKWALDER E,et al.In vivo turnover study demonstrates diminished clearance of lipoprotein(a)in hemodialysis patients[J]. Kidney Int,2007,71(10):1036-1043.
[10]	MIKOLASEVIC I,ŽUTELIJA M,MAVRINAC V,et al.Dyslipidemia in patients with chronic kidney disease:etiology and management[J]. Int J Nephrol Renovasc Dis,2017,10:35-45.
[11]	MCNEAL C J.Lipoprotein(a):its relevance to the pediatric population[J]. J Clin Lipidol,2015,9(5 Suppl):S57-S66.
[12]	GUAN W,CAO J,STEFFEN B T,et al.Race is a key variable in assigning lipoprotein(a)cutoff values for coronary heart disease risk assessment:the multi-ethnic study of atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2015,35(4):996-1001.
[13]	BOERWINKLE E,LEFFERT C C,LIN J,et al.Apolipoprotein(a)gene accounts for greater than 90% of the variation in plasma lipoprotein(a)concentrations[J]. J Clin Invest,1992,90(1):52-60.
[14]	MOOSER V,SCHEER D,MARCOVINA S M,et al.The Apo(a)gene is the major determinant of variation in plasma Lp(a)levels in African Americans[J]. Am J Hum Genet,1997,61(2):402-417.
[15]	KRAFT H G,LINGENHEL A,KÖCHL S,et al. Apolipoprotein(a)kringle Ⅳ repeat number predicts risk for coronary heart disease[J]. Arterioscler Thromb Vasc Biol,1996,16(6):713-719.
[16]	KAMSTRUP P R,TYBJAERG-HANSEN A,STEFFENSEN R,et al.Genetically elevated lipoprotein(a)and increased risk of myocardial infarction[J]. JAMA,2009,301(22):2331-2339.
[17]	DUMITRESCU L,GLENN K,BROWN-GENTRY K,et al.Variation in LPA is associated with Lp(a)levels in three populations from the third national health and nutrition examination survey[J]. PLoS One,2011,6(1):e16604.
[18]	LANKTREE M B,ANAND S S,YUSUF S,et al.Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a)in South Asians,Chinese,and European Caucasians[J]. Circ Cardiovasc Genet,2010,3(1):39-46.
[19]	DEO R C,WILSON J G,XING C,et al.Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a)levels in African Americans[J]. PLoS One,2011,6(1):e14581.
[20]	LI J,LANGE L A,SABOURIN J,et al.Genome- and exome-wide association study of serum lipoprotein(a)in the Jackson Heart Study[J]. J Hum Genet,2015,60(12):755-761.
[21]	MARCOVINA S M,KOSCHINSKY M L,ALBERS J J,et al.Report of the national heart,lung,and blood institute workshop on lipoprotein(a)and cardiovascular disease:recent advances and future directions[J]. Clin Chem,2003,49(11):1785-1796.
[22]	TSIMIKAS S,HALL J L.Lipoprotein(a)as a potential causal genetic risk factor of cardiovascular disease:a rationale for increased efforts to understand its pathophysiology and develop targeted therapies[J]. J Am Coll Cardiol,2012,60(8):716-721.
[23]	BERG K,DAHLÉN G,FRICK M H. Lp(a)lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease[J]. Clin Genet,1974,6(3):230-235.
[24]	CATAPANO A L,GRAHAM I,DE BACKER G,et al.2016 ESC/EAS guidelines for the management of dyslipidaemias[J]. Kardiol Pol,2016,74(11):1234-1318.
[25]	TSIMIKAS S.A test in context:lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.
[26]	KRONENBERG F.Human genetics and the causal role of lipoprotein(a)for various diseases[J]. Cardiovasc Drugs Ther,2016,30(1):87-100.
[27]	NSAIBIA M J,MAHMUT A,BOULANGER M C,et al.Autotaxin interacts with lipoprotein(a)and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease[J]. J Intern Med,2016,280(5):509-517.
[28]	KAMSTRUP P R,NORDESTGAARD B G.Lipoprotein(a)concentrations,isoform size,and risk of type 2 diabetes:a mendelian randomisation study[J]. Lancet Diabetes Endocrinol,2013,1(3):220-227.
[29]	SANTOS R D,RAAL F J,CATAPANO A L,et al.Mipomersen,an antisense oligonucleotide to apolipoprotein B-100,reduces lipoprotein(a)in various populations with hypercholesterolemia:results of 4 phase Ⅲ trials[J]. Arterioscler Thromb Vasc Biol,2015,35(3):689-699.
[30]	TSIMIKAS S,VINEY N J,HUGHES S G,et al.Antisense therapy targeting apolipoprotein(a):a randomised,double-blind,placebo-controlled phase 1 study[J]. Lancet,2015,386(10002):1472-1483.